Effects of Omega-3 in the treatment of violent schizophrenia patients

Abstract Objective: This study was designed to explore the relationship in between the daily consumption of fish oil (360 mg DHA + 540 mg EPA), and reduction of symptoms and violent behavior among patients with schizophrenia. Method: Fifty inpatients meeting ICD-10 criteria for schizophrenia and scoring more than four of Modified Overt Aggression Scale (MOAS) with antipsychotics treatment were randomly assigned to receive either fish oil (N = 28) or a placebo (N = 22) in a twelve week, double-blind supplementation trial. Assessments were performed at baseline and at weeks 4, 8 and 12. Results: The PANSS and CGI scores decreased at the week of 4, 8 and 12, but no differences were found between the two groups. MOAS scores declined significantly at weeks 4, 8 and 12. At week 12, MOAS scores of the fish oil group declined significantly than the placebo group ( t  = − 2.40, P